By Suherman Candra Maholtra 
In a significant advancement for the global effort to eradicate Human Immunodeficiency Virus (HIV), researchers at the University of Virginia (UVA) School of Medicine have identified a fundamental biological mechanism that explains why the virus remains so resilient against modern medicine. The study, published by scientists at the Myles H. Thaler Center for AIDS and Human Retrovirus Research, reveals that subtle genetic variations within a specific viral control system determine the speed of HIV replication and the stubbornness of its "latent" or dormant state. These findings provide a new roadmap for researchers attempting to "flush out" the virus from its hiding places, a critical step toward achieving a permanent cure.
While the advent of highly active antiretroviral therapy (ART) has transformed HIV from a terminal diagnosis into a manageable chronic condition, the virus remains a permanent resident in the bodies of those infected. ART can effectively reduce the viral load to undetectable levels, preventing the onset of AIDS and stopping the transmission of the virus to others. However, HIV possesses a unique ability to enter a state of latency, embedding its genetic material into the DNA of the host’s immune cells. In this dormant state, the virus is invisible to both the immune system and current pharmaceutical interventions. If a patient ceases ART, the virus invariably reemerges from these reservoirs, often with aggressive speed.
The Rev-RRE Axis: A Viral Control Center
The UVA research team, led by Patrick Jackson, MD, and Godfrey Dzhivhuho, PhD, focused their investigation on a complex regulatory system known as the Rev-RRE axis. To replicate and produce new viral particles, HIV must export its genomic RNA—which contains the instructions for building new viruses—from the nucleus of the infected host cell into the cytoplasm. This process is managed by a viral protein called Rev, which binds to a specific RNA structure within the virus called the Rev Response Element (RRE).
For decades, many in the scientific community viewed the Rev-RRE axis as a binary "on-off" switch. It was assumed that the system either worked, leading to viral replication, or it didn’t. However, the UVA study suggests a far more nuanced reality.
"Early on, many scientists thought that the Rev-RRE axis was merely an on-off switch for the virus. However, our recent studies have shown that it functions more like a rheostat," explained Marie-Louise Hammarskjold, MD, PhD, associate director of the Thaler Center. By functioning like a dimmer switch, or rheostat, the Rev-RRE axis allows the virus to fine-tune its activity. Subtle variations in the genetic sequence of either the Rev protein or the RRE structure can significantly alter the efficiency of RNA export. This, in turn, dictates how aggressively the virus replicates and how deeply it sinks into dormancy.
Implications for "Shock and Kill" Strategies
The discovery has immediate implications for the "shock and kill" approach, a prominent strategy in HIV cure research. The goal of "shock and kill" is to use latency-reversing agents (LRAs) to "shock" the dormant virus into becoming active again, making the infected cells visible so the immune system or targeted drugs can "kill" them.
Despite years of clinical trials, "shock and kill" has yet to result in a scalable cure. The UVA study offers a compelling explanation for this struggle. If a portion of the viral reservoir consists of HIV variants with low Rev-RRE activity, those viruses will be naturally resistant to reactivation. They require a much stronger "shock" to be brought out of hiding.
Godfrey Dzhivhuho, a lead author on the study, noted that overlooking Rev has been a missing link in latency research. "If a portion of the viral reservoir has low Rev-RRE activity, it will be more resistant to reactivation," Dzhivhuho said. "By enhancing the Rev-RRE axis, we may be able to induce a stronger and more complete latency reversal and bring us closer to strategies that can truly clear the virus."
A Global Perspective: From South Africa to Charlottesville
The research is informed by a global perspective, particularly through the experiences of Dr. Dzhivhuho. Before joining the UVA Thaler Center, Dzhivhuho’s career began in South Africa, a nation that has been disproportionately affected by the HIV epidemic. According to UNAIDS data, South Africa is home to approximately 7.8 million people living with HIV, the largest population of any country in the world.
Dzhivhuho first met UVA professors David Rekosh, PhD, and Marie-Louise Hammarskjold while they were teaching summer sessions at the University of Venda in South Africa. After obtaining his PhD in HIV immunology from the University of Cape Town, he moved to UVA to continue his work.
"Coming from South Africa, where HIV affects so many lives, I’ve always wanted to be part of the effort to end this epidemic," Dzhivhuho said. His personal drive highlights the human stakes of the research. While ART has saved millions of lives, the burden of lifelong medication—including potential side effects, the risk of drug resistance, and the social stigma—remains a heavy toll for those living with the virus.
Chronology of HIV Research Milestones
To understand the significance of the UVA discovery, it is essential to view it within the broader timeline of HIV/AIDS research:
- 1981: The first cases of what would later be known as AIDS are reported in the United States.
- 1983-1984: Researchers at the Pasteur Institute and the National Cancer Institute identify HIV as the cause of AIDS.
- 1987: The FDA approves AZT, the first antiretroviral drug.
- 1996: The introduction of Highly Active Antiretroviral Therapy (HAART) revolutionizes treatment, turning HIV into a manageable condition for those with access to medicine.
- 2008: The "Berlin Patient" (Timothy Ray Brown) is reported as the first person functionally cured of HIV following a bone marrow transplant for leukemia.
- 2010s: Focus shifts toward understanding the "latent reservoir"—the collection of dormant cells that prevent a standard cure.
- 2024: UVA scientists identify the Rev-RRE rheostat, providing a biological explanation for the variability in viral reactivation.
Supporting Data and Technical Analysis
The UVA study utilized sophisticated molecular modeling and cellular assays to measure the activity of different Rev-RRE variants. The researchers found that even single-nucleotide changes in the RRE structure could lead to a multi-fold difference in the efficiency of RNA export.
This variability is not just a laboratory curiosity; it is a survival strategy for the virus. By maintaining a spectrum of Rev-RRE activity, a single HIV infection can produce a diverse population of viruses. Some are optimized for rapid spread during the early stages of infection, while others are optimized for long-term persistence in the face of immune pressure or medical intervention.
Data from the study indicates that viruses with "low-activity" Rev-RRE systems are significantly harder to detect using standard assays. This suggests that the latent reservoir may be even more complex and heterogeneous than previously thought. Future cure strategies will likely need to be "poly-therapeutic," using a combination of agents to target these different levels of viral activity simultaneously.
Broader Impact on Public Health
The pursuit of an HIV cure is as much an economic and social imperative as it is a scientific one. According to the World Health Organization (WHO), as of 2022, approximately 39 million people globally were living with HIV. While 29.8 million of these individuals were accessing ART, millions still lack consistent treatment.
The cost of providing lifelong ART to tens of millions of people is staggering, particularly for low- and middle-income countries. A "functional cure"—defined as a treatment that allows the body to control the virus without daily medication—would alleviate the financial strain on global health systems and eliminate the risk of "treatment fatigue" among patients.
"HIV treatment is lifesaving but also lifelong," said Patrick Jackson, MD. "Understanding how the virus stays latent in cells could help us develop a lasting cure for HIV."
Future Directions and Research Funding
The findings at UVA open several new avenues for drug development. Potential future therapies might include:
- Rev-Enhancers: Compounds designed to artificially boost Rev-RRE activity in latent cells, making them more susceptible to "shock and kill" agents.
- Personalized Latency Mapping: Using genetic sequencing to determine the specific Rev-RRE profile of a patient’s viral reservoir to tailor treatment.
- Refining "Block and Lock": Conversely, some researchers are looking at the "block and lock" strategy—permanently silencing the virus so it can never reemerge. Understanding the Rev-RRE rheostat could help identify ways to turn the "dimmer switch" all the way to zero.
The research conducted at UVA was made possible through the Myles H. Thaler Research Support Gift and grants from the National Institutes of Health (NIH), specifically grants R21 AI134208 and K08 AI136671. The Thaler Center continues to be a hub for retrovirus research, fostering collaborations that bridge the gap between basic molecular biology and clinical application.
As the scientific community moves forward, the UVA study serves as a reminder that the key to defeating HIV may lie in its smallest details. By deciphering the subtle "rheostat" of the Rev-RRE axis, researchers are no longer just looking for a switch in the dark; they are beginning to understand the very mechanics of how the virus hides, bringing the world one step closer to a future without HIV.